Lupin inks commercial pact with Creso Pharma for cannaQIX

As per the agreement, Creso has given Pharma Dynamics sole distribution rights of its products across South Africa, Namibia, Botswana, Zimbabwe, Swaziland, Lesotho, Angola, Mozambique and Uganda, Lupin said in a statement.

New Delhi: Drug firm Lupin on Monday said it's South African arm Pharma Dynamics has signed a commercial agreement with Creso Pharma for hemp oil-based cannaQIX products.

As per the agreement, Creso has given Pharma Dynamics sole distribution rights of its products across South Africa, Namibia, Botswana, Zimbabwe, Swaziland, Lesotho, Angola, Mozambique and Uganda, Lupin said in a statement.

"We hope that this agreement will form the foundation of a longstanding relationship as we grow our footprint from nutraceuticals into the scheduled market as well," Pharma Dynamics CEO Erik Roos said.

Creso Pharma is globally recognized as a leader in the production of cannabis products with distribution agreements already in place in various countries in Europe and Asia-Pacific, he added.

Read Also: Lupin, Glenmark recalls hypertension, fungal infection drugs from US market

"We are encouraged to see a wide range of opportunities opening up to bring premium hemp oil nutraceutical products to customers in South Africa," Creso Pharma CEO and co-founder Miri Halperin Wernli said.

Read Also: Lupin unveils generic version of Prozac tablets in US

The cannaQIX range of products is cannabidiol hemp oil-based nutraceuticals that are used for reducing stress and to support mental and nervous functions.

Read Also: Lupin to sell Japanese injectables business to Abu-Dhabi based Neopharma group